Axsome Therapeutics to Present Data Spanning the SYMBRAVO® (meloxicam and rizatriptan) Clinical Program at the 67th Annual Scientific Meeting of the American Headache Society (AHS)

Core Insights - Axsome Therapeutics, Inc. is presenting data from the SYMBRAVO clinical program at the 67th Annual Scientific Meeting of the American Headache Society, highlighting its advancements in treating central nervous system disorders [1] Group 1: SYMBRAVO Clinical Data - The SYMBRAVO program includes multiple presentations, such as the efficacy of SYMBRAVO based on migraine-associated disability from the INTERCEPT trial [1] - Long-term effects of SYMBRAVO on headache burden and quality of life will be discussed, showcasing results from the MOVEMENT trial [1] - Topline results from the EMERGE trial will focus on the efficacy and safety of SYMBRAVO in patients with inadequate response to oral CGRP inhibitors [1] Group 2: Product Information - SYMBRAVO is a novel oral medication combining meloxicam and rizatriptan, approved for acute migraine treatment in adults [2] - The formulation utilizes MoSEIC technology for rapid absorption and prolonged plasma half-life, aiming for effective migraine pain relief [2] - SYMBRAVO is not intended for migraine prevention or treatment of specific types of migraines such as hemiplegic or basilar migraines [4] Group 3: Company Overview - Axsome Therapeutics focuses on innovative treatments for central nervous system conditions, with a portfolio that includes FDA-approved therapies for major depressive disorder and narcolepsy [30] - The company aims to address significant gaps in care through differentiated products and novel mechanisms of action [30] - Axsome's mission is to improve patient outcomes for neurological and psychiatric conditions affecting over 150 million people in the U.S. [30]